Ken André OLAUSSEN
机构: Maître de conférences (Associate Professor), University of Paris Sud
每年引用次数
引用次数
引用: 7,036
H-指数: 35
I10-指数 : 53
出版物: 110
Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
Ilio Vitale , Lorenzo Galluzzi , Sonia Vivet , Lisa Nanty
PLoS ONE 2 ( 12) e1337
69
2007
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
Gonzalo Recondo , Laura Mezquita , Francesco Facchinetti , David Planchard
Clinical Cancer Research 26 ( 1) 242 -255
31
2020
Facts and new hopes on selective FGFR inhibitors in solid tumors
Francesco Facchinetti , Antoine Hollebecque , Rastislav Bahleda , Yohann Loriot
Clinical Cancer Research 26 ( 4) 764 -774
18
2020
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Ken A Olaussen , Julien Adam , Elsa Vanhecke , Philippe Vielh
Lung Cancer 80 ( 2) 216 -222
30
2013
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
J Chen , F Facchinetti , F Braye , AA Yurchenko
Annals of Oncology 33 ( 4) 434 -444
4
2022
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
S Postel-Vinay , I Bajrami , L Friboulet , R Elliott
Oncogene 32 ( 47) 5377 -5387
63
2013
Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions
CM Raynaud , Se-Jin Jang , Paolo Nuciforo , Sylvie Lantuejoul
Annals of Oncology 19 ( 11) 1875 -1881
43
2008
Immunohistochemical staining of the Excision Repair Cross-Complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT)
J Soria , V Haddad , KA Olaussen , P Fouret
Journal of Clinical Oncology 24 7010 -7010
12
2006
Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC
KA Olaussen , J-C Soria , YW Park , HJ Kim
European Journal of Cancer 41 ( 14) 2112 -2119
26
2005
288 Synthetic Lethality in ERCC1-deficient Non-Small Cell Lung Cancer
S Postel-Vinay , I Bajrami , L Friboulet , I Jaco
European Journal of Cancer 48 88
2012
ERCC1 REMAINS A PREDICTIVE MARKER OF THE BENEFIT OF ADJUVANT CHEMOTHERAPY (CT) IN THE UPDATED INTERNATIONAL LUNG CANCER TRIAL (IALT)
JC Soria , KA Olaussen , AL Vataire , A Dunant
ANNALS OF ONCOLOGY 19 92 -92
2008
Increased incidence of brain metastases in ERCC1-negative NSCLC patients treated with adjuvant cisplatin-based chemotherapy
B Besse , C Massard , V Haddad , F André
Journal of Clinical Oncology 25 ( 18_suppl) 7581 -7581
2007
MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer
P Fouret , D Planchard , J Mendiboure , NS Kamal
Journal of Clinical Oncology 27 ( 18_suppl) CRA7502 -CRA7502
23
2009
ERCC1 and lung cancer
D Planchard , KA Olaussen , JC Soria
Revue des Maladies Respiratoires 27 ( 4) 387 -394
3
2010
European Society for Medical Oncology and the Japanese Society of Medical Oncology
H Wildiers , E Brain , A Castells , A Cervantes
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
WE Pierceall , KA Olaussen , V Rousseau , E Brambilla
Annals of Oncology 23 ( 9) 2245 -2252
79
2012
9009 ORAL Immunohistochemical Analysis of a Panel of DNA Repair Proteins in NSCLC Predict for Cisplatin Benefit in Resected Squamous-cell Carcinoma but Not in Adenocarcinoma
K.A. Olaussen , W.E. Pierceall , K.M. Sprott , D.T. Weaver
European Journal of Cancer 47
2011
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
B. Besse , C. Massard , V. Haddad , F. Andre
Annals of Oncology 22 ( 3) 575 -581
10
2011
Predictors of chemotherapy efficacy in Non-Small Cell Lung Cancer : a challenging landscape
K.A. Olaussen , S. Postel-Vinay
Annals of Oncology 27 ( 11) 2004 -2016
57
2016